Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 4
2016 4
2017 5
2018 6
2019 5
2020 17
2021 13
2022 20
2023 29
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Attard G, et al. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953525 Free PMC article.
Frontiers of Ovarian Carcinosarcoma.
Ismail A, Choi S, Boussios S. Ismail A, et al. Among authors: boussios s. Curr Treat Options Oncol. 2023 Dec;24(12):1667-1682. doi: 10.1007/s11864-023-01138-4. Epub 2023 Nov 8. Curr Treat Options Oncol. 2023. PMID: 37938504 Free PMC article. Review.
State-of-the-Art Molecular Oncology in UK.
Sandoughdaran S, Mikropoulos C, Boussios S. Sandoughdaran S, et al. Among authors: boussios s. Int J Mol Sci. 2023 May 26;24(11):9336. doi: 10.3390/ijms24119336. Int J Mol Sci. 2023. PMID: 37298288 Free PMC article.
Frontiers of Molecular Biology of Cancer.
Boussios S, Sanchez E, Sheriff M. Boussios S, et al. Int J Mol Sci. 2023 Dec 6;24(24):17187. doi: 10.3390/ijms242417187. Int J Mol Sci. 2023. PMID: 38139014 Free PMC article.
Medical oncology: challenges in 2022.
Boussios S, Sanchez E, Sheriff M. Boussios S, et al. Ann Palliat Med. 2024 Jan;13(1):22-30. doi: 10.21037/apm-23-572. Epub 2024 Jan 9. Ann Palliat Med. 2024. PMID: 38199801 Free article. No abstract available.
Advances in adoptive T-cell therapy for metastatic melanoma.
Das A, Ghose A, Naicker K, Sanchez E, Chargari C, Rassy E, Boussios S. Das A, et al. Among authors: boussios s. Curr Res Transl Med. 2023 Jul-Sep;71(3):103404. doi: 10.1016/j.retram.2023.103404. Epub 2023 Jul 7. Curr Res Transl Med. 2023. PMID: 37478776 Review.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators. Attard G, et al. Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1. Lancet Oncol. 2023. PMID: 37142371 Free article.
Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E, Papadopoulos V, Ghose A, Boussios S. Aweys H, et al. Among authors: boussios s. Anticancer Res. 2023 Nov;43(11):4781-4792. doi: 10.21873/anticanres.16675. Anticancer Res. 2023. PMID: 37909991 Review.
108 results